Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs.#Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future ...
GLP-1 Benefits GLP-1s work by slowing stomach emptying, which results in greater feelings of fullness and decreased appetite. They also stimulate the release of insulin from the pancreas to regulate blood sugar in response to meals. People taking GLP-1s lose, on average, 13% of their body ...
If you’ve started taking a GLP-1 drug and are struggling with nausea, you’re not alone. A reported 50% of users taking the GLP-1 medications experience nausea. Understanding why this happens and how to mitigate it can help you stay on track with your treatment plan. Understanding Nausea...
There are several risk factors regarding further adoption of the treatment. However, these mostly depend on a stabilized supply-chain of GLP-1 production, further development of the medication into a potential pill format, expanded health insurance coverage (including Medicare), FDA approval for obesi...
Two new fixed-dose basal/GLP-1 receptor-agonist agents, Soliqua 100/33 (Sanofi) and Xultophy 100/3.6 (Novo Nordisk), were approved by the FDA in November 2016.
Beard, 47, had previously sought a GLP-1 prescription, but her doctor "wouldn't even try" to get it approved, assuming her insurance company would reject coverage of the costly medication, she said. GLP-1s cost roughly $1,000 per month before insurance and other rebates. ...
Learn about the reasons your health insurance plan requires prior authorization for certain medical procedures.
Learn about limitations and options for managing your oral health under Medicare and other insurance plans. Paul WynnFeb. 12, 2025 Does Medicare Cover Cataract Surgery? Learn about Medicare's coverage for cataract surgery and any out-of-pocket costs you may need to pay. ...
Continuous glucose monitors provide a way to keep tabs on blood glucose levels without fingerpricks. However, these systems can be costly — even with insurance.
Mike, Anthony, and Karthik are joined by new recurring host Amy Huras, Director of Research at Lux, to unpack how the new class of GLP-1 drugs will impact the production of food. Will your local pizza place survive? Plus, Massachusetts’ plan to become a climate tech powerhouse. ...